You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The test runs on Qiagen's Rotor-Gene Q MDx system and is designed to qualitatively detect the JAK2 V617F/G1849T allele in genomic DNA from whole blood.
The ASPIRE algorithm uses cell phenotype information from bone marrow samples to predict which patients will relapse and which will go into remission.
The companies plan to codevelop Adaptive's ClonoSeq assay to measure minimal residual disease in ALL.
The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.